Published 9 hours ago • loading... • Updated 4 hours ago

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

Summary by CNBC

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

4 Articles

CNBC

+2 Reposted by 2 other sources

Lean Left

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

9 hours ago·Englewood Cliffs, United States

Read Full Article

SpaceMoney

Lilly Sees 70% of New GLP-1 Patients in Medicare

According to CNBC, CEO of Eli Lilly claims that 700,000 new beneficiaries of Medicare have started GLP-1 since July and 70% use medicines from the company

6 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources4

Leaning Left2Leaning Right0Center0Last Updated4 hours agoBias Distribution

100% Left

Bias Distribution

100% of the sources lean Left

100% Left

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

CNBC broke the news in Englewood Cliffs, United States 9 hours ago on Monday, September 21, 2026.

Sources are mostly out of (0)

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

4 Articles

4 Articles

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

Lilly Sees 70% of New GLP-1 Patients in Medicare

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Are GLP-1s the new statins?

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Drugs, Anti-Obesity Semaglutide at the Center of the New Cardio-Renal Protection

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Similar News Topics

Similar News Topics

More stories like this

Are GLP-1s the new statins?

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Drugs, Anti-Obesity Semaglutide at the Center of the New Cardio-Renal Protection

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

Roughly 70% of the new patients are taking Lilly medicines, with Zepbound emerging as the main beneficiary, CEO Dave Ricks said.

4 Articles

4 Articles

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

Translate IconLilly Sees 70% of New GLP-1 Patients in Medicare

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Are GLP-1s the new statins?

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Drugs, Anti-Obesity Semaglutide at the Center of the New Cardio-Renal Protection

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Similar News Topics

Similar News Topics

More stories like this

Are GLP-1s the new statins?

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

GLP-1 drugmakers sued over sudden vision loss risk: Reports

Drugs, Anti-Obesity Semaglutide at the Center of the New Cardio-Renal Protection

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Lilly Sees 70% of New GLP-1 Patients in Medicare

Bias Distribution

Factuality